US Stock MarketDetailed Quotes
LIXT Lixte Biotechnology
- 2.6700
- -0.0950-3.44%
Trading May 9 11:52 ET
6.01MMarket Cap-1003P/E (TTM)
2.7200High2.6700Low3.73KVolume2.7400Open2.7650Pre Close10.05KTurnover0.19%Turnover RatioLossP/E (Static)2.25MShares9.500052wk High12.14P/B5.28MFloat Cap1.580052wk Low--Dividend TTM1.98MShs Float71.9000Historical High--Div YieldTTM1.81%Amplitude1.5800Historical Low2.6940Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Lixte Biotechnology Stock Forum
How big is the GVHD market?
US$ 2.71 billion
The Graft Versus Host Disease (GVHD) Treatment Market in 2023 is US$ 2.71 billion, and is expected to reach US$ 5.17 billion by 2031 at a CAGR of 8.42%. FutureWise Research published a report that analyzes Graft Versus Host Disease (GVHD) Treatment Market trends to predict the market's growth.Feb 6, 2024
Benzinga· 9 mins ago
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS
• The dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LB-100 to GSK's dostarlimab-gxly will enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). The clinical trial was initiated by, and is being conducted at, the University of Texas MD Anderson Cancer Center. LIXTE is providing LB-100, and GSK is providing dostarlimab-...
3 MINUTES AGO, 8:30 AM EDT
VIA GLOBENEWSWIRE
No comment yet